Table 1.
Propensity‐score matching (PSM) before and after Roux‐en‐Y gastric bypass (RYGB) surgery. Control subjects were propensity‐score matched 2:1, to patients before (pre‐RYGB) and 5 years after (post‐RYGB) RYGB. Data are presented as median and 25% interquartile range. P‐values were calculated by Wilcoxon's nonparametric test for continuous parameters and Pearson's chi square test for categorical parameters. Measures highlighted in italics were included for the PSM. Lipolysis is μmoles of glycerol release per 2 h
| Measure | PSM control, n = 244 | Post‐RYGB, n = 122 | p‐Value |
|---|---|---|---|
| Age (years) | 48.0 (41.0–56.0) | 49.0 (42.0–55.0) | 0.59 |
| Sex | 0.62 | ||
| Women | 218 (89.3%) | 107 (87.7%) | |
| Men | 26 (10.7%) | 15 (12.3%) | |
| Body mass index (kg/m2) | 27.65 (24.35–34.95) | 29.55 (26.70–31.70) | 0.20 |
| Waist‐to‐hip ratio | 0.93 (0.87–0.98) | 0.92 (0.88–0.97) | 0.92 |
| Body fat (kg) | 30 (25–43) | 30 (25–36) | 0.14 |
| Fat cell volume (nanolitres) | 0.64 (0.50–0.80) | 0.43 (0.36–0.58) | <0.0001 |
| ISO lipolysis/g lipid | 3.98 (2.71–5.49) | 2,98 (2.29–3.76) | <0.0001 |
| ISO lipolysis/107 fat cells | 22.44 (15.1–31.2) | 11.8 (8.57–16.7) | <0.0001 |
| Basal lipolysis/g lipid | 0.72 (0.48–1.29) | 0.67 (0.52–0.89) | 0.16 |
| Basal lipolysis/107 fat cells | 4.18 (2.19–8.07) | 2.83 (1.99–3.77) | <0.0001 |
| NA lipolysis/g lipid | 2.13 (1.31–3.40) | 1.52 (1.10–1.95) | <0.0001 |
| NA lipolysis/107 fat cells | 12.42 (6.61–20.48) | 5.98 (4.27–8.61) | <0.0001 |
| Diabetes (yes/no) | 28/216 | 0/122 | <0.0001 |
| Hyperlipidemia (yes/no) | 13/231 | 1/121 | 0.07 |
| Hypertension (yes/no) | 36/208 | 24/98 | 0.29 |
| Physical activity (score) | 2 (1–2) | 2 (2–2) | 0.08 |
| P‐glucose (mmol/L) | 5.3 (4.9–6.0) | 5.0 (4.8–5.4) | 0.0002 |
| P‐cholesterol (mmol/L) | 5.1 (4.4–5.9) | 4.2 (3.8–4.9) | <0.0001 |
| P‐HDL‐cholesterol (mmol/L) | 1.3 (1.1–1.6) | 1.6 (1.3–1.8) | <0.0001 |
| P‐triglycerides (mmol/L) | 1.2 (0.80–1.65) | 0.89 (0.66–1.2) | <0.0001 |
| HOMA (units) | 1.8 (1.2–3.3) | 0.2 (0.1–1.0) | <0.0001 |
Abbreviations: HDL, high‐density lipoprotein; HOMA, homeostasis model assessment of insulin sensitivity; ISO, isoprenaline; NA, noradrenaline; P, fasting plasma.